Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 30 September 2022, including: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after lecanemab results; Leqvio’s importance to Novartis AG; Pfizer Inc.’s secret sauce for digitization; and Amgen, Inc.’s clinical trial diversity initiatives.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "A Banner Moment For Alzheimer's Positions Eisai/Biogen At The Head Of The Pack" - Scrip, 27 Sep, 2022.)

(Also see "Rising Tide Lifts Many Ships In Wake Of Eisai/Biogen’s Lecanemab Readout" - Scrip, 28 Sep, 2022.)

(Also see "Leqvio Launch Will Be Fundamental To Success Of New Novartis" - Scrip, 23 Sep, 2022.)

(Also see "Pfizer Reveals Secret Digital Sauce To Cut Trial Duration, MLR Review Times" - Scrip, 28 Sep, 2022.)

(Also see "Amgen VP Encouraged By Initial Clinical Trial Diversity Efforts" - Scrip, 26 Sep, 2022.)

 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel